PIN67 MODELING G-DRG REVENUE WHEN HOSPITALIZATION DURATION FROM CLINICAL TRIALS IS AVAILABLE:THE CASE OF DORIPENEM VERSUS IMIPENEM IN TREATING VENTILATOR-ASSOCIATED PNEUMONIA (VAP) IN GERMANY